Christy Oliger

Christy Oliger is an accomplished board director and executive with extensive experience in the biopharmaceutical industry. Currently serving as an Independent Board Director for multiple companies including Vera Therapeutics, Inc., LAVA Therapeutics N.V., Replimune, and Karyopharm Therapeutics Inc., Oliger has been involved in significant acquisitions such as RayzeBio's acquisition by BMS and Reata Pharmaceuticals' acquisition by Biogen. Previous leadership roles at Genentech spanned from Senior Vice President for various business units to other senior management positions, demonstrating a strong background in oncology, neuroscience, and rare diseases, as well as portfolio management. Oliger's early career at Schering-Plough included pivotal marketing and managerial roles. Oliger holds a Bachelor's degree in Economics from the University of California at Santa Barbara.